Back to Screener

Healthcare

Bristol-Myers Squibb Company Ce(CELG-RI)

Live Price

Offline

$0.1295

+24.64% today

Window Change

+355.99%

Window

Jun 23, 2025 โ†’ May 15, 2026

Market Cap
$264.45M
Revenue Growth
-0.2%
EPS Growth
+178.7%
Dividend Yield
0.0%

Coverage: 225 bars ยท Jun 23, 2025 โ†’ May 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Bristol-Myers Squibb Company Ce (CELG-RI) is a Healthcare stock with a market cap of $264.45M. The stock last traded around $0.13 and up 356.0% across the available one-year price window (Jun 23, 2025 โ†’ May 15, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +178.7%, a dividend yield of 0.0%. What stands out right now is revenue -0.2%, EPS +178.7%, free cash flow -7.9% with operating margin 34.0% and ROIC 13.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CELG-RI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

CELG-RI

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

CELG-RI Max Drawdown

-64.27%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CELG-RI and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

1.32

Range 1.32 โ†’ 1.32

No analyst count

vs prior: +5.1%

Revenue Outlook

$10.2B

Range $10.2B โ†’ $10.2B

No analyst count

vs prior: +2.5%

Consensus Spread

EPS spread0.0%
Revenue spread0.0%

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

1.32
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +5.1%

Trend

Revenue trend

Average analyst revenue estimate

$10.2B
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +2.5%

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q4 2028
Ends Dec 31, 2028
quarter
Revenue
$10.2B
$10.2B to $10.2B
EPS
1.32
1.32 to 1.32
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates
Q3 2028
Ends Sep 30, 2028
quarter
Revenue
$9.9B
$9.9B to $9.9B
EPS
1.26
1.26 to 1.26
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates
Q2 2028
Ends Jun 30, 2028
quarter
Revenue
$10.2B
$10.2B to $10.2B
EPS
1.31
1.31 to 1.31
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates
Q1 2028
Ends Mar 31, 2028
quarter
Revenue
$9.9B
$9.9B to $9.9B
EPS
1.21
1.21 to 1.21
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates
Q4 2027
Ends Dec 31, 2027
quarter
Revenue
$12.1B
$12.1B to $12.1B
EPS
1.55
1.55 to 1.55
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates
Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$11.6B
$11.6B to $11.6B
EPS
1.53
1.53 to 1.53
No analyst count
EPS: No analyst count
May 5, 12:18 PM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.